Nasdaq

Clearside Biomedical Details Phase 3 Program for CLS-AX in Wet AMD Following Positive FDA ...

Receipt of formal meeting minutes from the FDA confirming key elements for two proposed Phase 3 pivotal trials indicates regulatory progress and alignment with the FDA. Positive outcome of the ...
Seeking Alpha

Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD

CEO George Lasezkay highlighted the company's progress in advancing its suprachoroidal delivery platform, noting over 15,000 suprachoroidal injections performed to date. He announced alignment with ...
The New York Times

Argentina’s Leader Takes Ax to Program That Drove Down Teen Pregnancy

Argentina has been known as one of Latin America’s most socially progressive countries. But President Javier Milei’s austerity measures have cut programs aimed at helping women. Argentina has been ...
Nasdaq

Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at ...

Clearside Biomedical announces upcoming presentations on CLS-AX sub-group analyses from the ODYSSEY Wet AMD trial at various conferences. Clearside Biomedical, Inc. announced upcoming presentations ...
Business Insider

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the ...

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration of ...